Voloridge Investment Management
CCCC icon

Voloridge Investment Management’s C4 Therapeutics CCCC Stock Holding History

Voloridge Investment Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-107,568
Closed -$943K – 1453
2022
Q3 		$943K Sell
107,568
-156,362
-59% -$1.62M 0.01% 1168
2022
Q2 		$1.99M Buy
+263,930
New +$2.32M 0.01% 1017
2022
Q1 		– Sell
-60,903
Closed -$1.96M – 1391
2021
Q4 		$1.96M Sell
60,903
-44,411
-42% -$1.76M 0.01% 1076
2021
Q3 		$4.71M Buy
105,314
+9,036
+9% +$387K 0.03% 708
2021
Q2 		$3.64M Buy
+96,278
New +$3.45M 0.03% 751

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management's CCCC Position: Q4 2022 in Review

Voloridge Investment Management sold out of C4 Therapeutics (CCCC) in Q4 2022, closing a stake of 107,568 shares — an estimated $943K sold.

Voloridge Investment Management first reported a position in CCCC in Q2 2021 and held it in 5 quarters. The position peaked at $4.71M in Q3 2021. 117 funds tracked by Wall St. Rank hold CCCC as of Q4 2022.

  • Voloridge Investment Management reported no remaining C4 Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 107,568 C4 Therapeutics shares in Q4 2022, an estimated $943K.
  • Voloridge Investment Management first reported a position in C4 Therapeutics in Q2 2021 and held it in 5 quarters.
  • Voloridge Investment Management's C4 Therapeutics position peaked at $4.71M in Q3 2021.
  • 117 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2022.

Based on Voloridge Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.